BTSG vs CTKB: fair value comparison
BrightSpring Health Services, Inc. and Cytek Biosciences, Inc. · Updated 2026-10-19
CTKB is still awaiting a full valuation verdict under our six-validated-windows standard. Within Healthcare, BTSG currently ranks higher by quality score.
| BTSG | CTKB | |
|---|---|---|
| Verdict | Undervalued | Awaiting full valuation |
| Last price | $60.87 | $5.25 |
| 12-month range | $31.36–$72.91 | $3.35–$6.09 |
| Rank by discount to fair value | #35 of 108 Healthcare | — |
| Rank by quality score | #153 of 301 Healthcare | #155 of 301 Healthcare |
| Quality grade | D | D |
| Leverage | Moderate | Low |
| Margin trend | Stable | Stable |
| Revenue growth | Strong | Modest |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Uptrend | Uptrend |
| 52-week position | The upper-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: BTSG fair value analysis · CTKB fair value analysis